

**NEOPROBE TO PRESENT AT ONEMEDPLACE FINANCE FORUM  
CEO to Provide Business and Product Development Update**

DUBLIN, OHIO – January 11, 2010 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that David Bupp, Neoprobe's President and Chief Executive Officer, will deliver a corporate presentation at the OneMedPlace Finance Forum at 4:00PM PST on Tuesday, January 12, 2010 at the Sir Francis Drake Hotel in San Francisco. Held annually, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners.

A replay of the presentation will be available in the Investor Relations section of the Company's website, [www.neoprobe.com](http://www.neoprobe.com) the following morning and will remain available for one week following the conference.

**About Neoprobe**

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe<sup>®</sup> GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek<sup>®</sup> and RIGScan<sup>®</sup> CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. [www.neoprobe.com](http://www.neoprobe.com)